HBIO Cash-Secured Put Strategy

HBIO (Harvard Bioscience, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

HBIO (Harvard Bioscience, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $27.2M, a beta of 1.51 versus the broader market, a 52-week range of 3.8-9.4, average daily share volume of 42K, a public-listing history dating back to 2001, approximately 331 full-time employees. These structural characteristics shape how HBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.51 indicates HBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a cash-secured put on HBIO?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current HBIO snapshot

As of June 30, 2026, spot at $6.00, ATM IV 120.80%, IV rank 21.38%, expected move 34.63%. The cash-secured put on HBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 52-day expiry.

Why this cash-secured put structure on HBIO specifically: HBIO IV at 120.80% is on the cheap side of its 1-year range, which means a premium-selling HBIO cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 34.63% (roughly $2.08 on the underlying). The 52-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on HBIO should anchor to the underlying notional of $6.00 per share and to the trader's directional view on HBIO stock.

HBIO cash-secured put setup

The HBIO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HBIO near $6.00, the first option leg uses a $5.70 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HBIO chain at a 52-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HBIO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$5.70N/A

HBIO cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

HBIO cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on HBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on HBIO

Cash-secured puts on HBIO earn premium while a trader waits to acquire HBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning HBIO.

HBIO thesis for this cash-secured put

The market-implied 1-standard-deviation range for HBIO extends from approximately $3.92 on the downside to $8.08 on the upside. A HBIO cash-secured put lets a trader earn premium while waiting to acquire HBIO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current HBIO IV rank near 21.38% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on HBIO at 120.80%. As a Healthcare name, HBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HBIO-specific events.

HBIO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HBIO alongside the broader basket even when HBIO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on HBIO carry tail risk when realized volatility exceeds the implied move; review historical HBIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current HBIO chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on HBIO?
A cash-secured put on HBIO is the cash-secured put strategy applied to HBIO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With HBIO stock trading near $6.00, the strikes shown on this page are snapped to the nearest listed HBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are HBIO cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the HBIO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 120.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a HBIO cash-secured put?
The breakeven for the HBIO cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HBIO market-implied 1-standard-deviation expected move is approximately 34.63%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on HBIO?
Cash-secured puts on HBIO earn premium while a trader waits to acquire HBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning HBIO.
How does current HBIO implied volatility affect this cash-secured put?
HBIO ATM IV is at 120.80% with IV rank near 21.38%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related HBIO analysis